Clinical Trial Update: Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating oral TAK-593 in adults with nonhematologic advanced solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• TAK-593

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED